Yasmin Abdelrazek Ali, Alaa Roushdy, Mohammed Abdullah Hegab, Amr Mansour Mohammed
{"title":"右心室后肺动脉导管:短期和中期结果:单中心研究","authors":"Yasmin Abdelrazek Ali, Alaa Roushdy, Mohammed Abdullah Hegab, Amr Mansour Mohammed","doi":"10.1186/s43057-023-00115-9","DOIUrl":null,"url":null,"abstract":"Surgery for congenital heart disease has progressed by leaps and bounds in the last few decades, but the right ventricular outflow tract continues to pose a challenge to the congenital heart surgeon. We aim to describe the outcomes of patients with CHD who had surgical placement of right ventricle to pulmonary artery conduits with a focus on the risk factors for redo-surgery. We performed a retrospective single-center clinical data review of patients who had RVOT surgery using RV-to-PA conduits Thirty-three patients (54.5% males) were included. The mean age at first conduit placement was 3.57 ± 3.18 years, mean conduit size conduit was 14.45 ± 3.85 mm. 51.5% of patients received Contegra tubes. On a mean follow-up of 2.07 ± 2.36 years, 45.5% of patients underwent RV-to-PA conduits redo replacement after 5.67 ± 3.25 years from the first surgery, 2 patients underwent re-intervention for the second time, 7 patients had transcatheter interventions on RVOT or branch PAs. The main mode of conduit failure was stenosis. The median survival without the need for surgical reintervention was 2.5 years for the non-contegra subgroup versus 3 years for the contegra subgroup (P = 0.59). we predicted that 100% of the study group would require redo surgery for conduit replacement within the first 11 years post-initial surgery. For every year of age increase at follow-up, the hazard ratio for redo surgery increases by a factor of 1.47. For every year of age increase at the time of first operation, the hazard ratio for redo surgery decreases by a factor of 0.7. The use of conduits to treat the RV to PA discontinuity is a cornerstone in treating congenital heart diseases. Nevertheless, conduit failure and replacement are inevitable. In our experience the higher the age at the first conduit, the longer the re-intervention-free survival period.","PeriodicalId":501458,"journal":{"name":"The Cardiothoracic Surgeon","volume":"10 1","pages":""},"PeriodicalIF":0.0000,"publicationDate":"2023-11-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Post-right ventricle to pulmonary artery conduit: short- and intermediate-term outcomes: a single-center study\",\"authors\":\"Yasmin Abdelrazek Ali, Alaa Roushdy, Mohammed Abdullah Hegab, Amr Mansour Mohammed\",\"doi\":\"10.1186/s43057-023-00115-9\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"Surgery for congenital heart disease has progressed by leaps and bounds in the last few decades, but the right ventricular outflow tract continues to pose a challenge to the congenital heart surgeon. We aim to describe the outcomes of patients with CHD who had surgical placement of right ventricle to pulmonary artery conduits with a focus on the risk factors for redo-surgery. We performed a retrospective single-center clinical data review of patients who had RVOT surgery using RV-to-PA conduits Thirty-three patients (54.5% males) were included. The mean age at first conduit placement was 3.57 ± 3.18 years, mean conduit size conduit was 14.45 ± 3.85 mm. 51.5% of patients received Contegra tubes. On a mean follow-up of 2.07 ± 2.36 years, 45.5% of patients underwent RV-to-PA conduits redo replacement after 5.67 ± 3.25 years from the first surgery, 2 patients underwent re-intervention for the second time, 7 patients had transcatheter interventions on RVOT or branch PAs. The main mode of conduit failure was stenosis. The median survival without the need for surgical reintervention was 2.5 years for the non-contegra subgroup versus 3 years for the contegra subgroup (P = 0.59). we predicted that 100% of the study group would require redo surgery for conduit replacement within the first 11 years post-initial surgery. For every year of age increase at follow-up, the hazard ratio for redo surgery increases by a factor of 1.47. For every year of age increase at the time of first operation, the hazard ratio for redo surgery decreases by a factor of 0.7. The use of conduits to treat the RV to PA discontinuity is a cornerstone in treating congenital heart diseases. Nevertheless, conduit failure and replacement are inevitable. In our experience the higher the age at the first conduit, the longer the re-intervention-free survival period.\",\"PeriodicalId\":501458,\"journal\":{\"name\":\"The Cardiothoracic Surgeon\",\"volume\":\"10 1\",\"pages\":\"\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2023-11-16\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"The Cardiothoracic Surgeon\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.1186/s43057-023-00115-9\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"The Cardiothoracic Surgeon","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1186/s43057-023-00115-9","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0
摘要
在过去的几十年里,先天性心脏病的外科手术取得了突飞猛进的发展,但右心室流出道仍然是先天性心脏外科医生面临的一个挑战。我们的目的是描述手术放置右心室至肺动脉导管的冠心病患者的结果,重点是再手术的危险因素。我们对使用rv - pa导管进行RVOT手术的患者进行了回顾性的单中心临床资料回顾,包括33例患者(54.5%为男性)。首次放置导管的平均年龄为3.57±3.18岁,平均导管尺寸为14.45±3.85 mm, 51.5%的患者使用Contegra导管。在平均2.07±2.36年的随访中,45.5%的患者在第一次手术后5.67±3.25年进行了rv - pa导管重做置换术,2例患者进行了第二次再干预,7例患者在RVOT或分支pa上进行了经导管干预。导管衰竭的主要形式为狭窄。非整合亚组无需再手术干预的中位生存期为2.5年,整合亚组为3年(P = 0.59)。我们预测,100%的研究组在首次手术后的前11年内需要重新手术进行导管置换术。随访时年龄每增加一年,重做手术的风险比增加1.47倍。第一次手术时年龄每增加一岁,重做手术的风险比降低0.7倍。使用导管治疗左心室到左心室的不连续性是治疗先天性心脏病的基石。然而,水管故障和更换是不可避免的。根据我们的经验,第一次导管的年龄越高,无再介入生存期越长。
Post-right ventricle to pulmonary artery conduit: short- and intermediate-term outcomes: a single-center study
Surgery for congenital heart disease has progressed by leaps and bounds in the last few decades, but the right ventricular outflow tract continues to pose a challenge to the congenital heart surgeon. We aim to describe the outcomes of patients with CHD who had surgical placement of right ventricle to pulmonary artery conduits with a focus on the risk factors for redo-surgery. We performed a retrospective single-center clinical data review of patients who had RVOT surgery using RV-to-PA conduits Thirty-three patients (54.5% males) were included. The mean age at first conduit placement was 3.57 ± 3.18 years, mean conduit size conduit was 14.45 ± 3.85 mm. 51.5% of patients received Contegra tubes. On a mean follow-up of 2.07 ± 2.36 years, 45.5% of patients underwent RV-to-PA conduits redo replacement after 5.67 ± 3.25 years from the first surgery, 2 patients underwent re-intervention for the second time, 7 patients had transcatheter interventions on RVOT or branch PAs. The main mode of conduit failure was stenosis. The median survival without the need for surgical reintervention was 2.5 years for the non-contegra subgroup versus 3 years for the contegra subgroup (P = 0.59). we predicted that 100% of the study group would require redo surgery for conduit replacement within the first 11 years post-initial surgery. For every year of age increase at follow-up, the hazard ratio for redo surgery increases by a factor of 1.47. For every year of age increase at the time of first operation, the hazard ratio for redo surgery decreases by a factor of 0.7. The use of conduits to treat the RV to PA discontinuity is a cornerstone in treating congenital heart diseases. Nevertheless, conduit failure and replacement are inevitable. In our experience the higher the age at the first conduit, the longer the re-intervention-free survival period.